Navigation Links
New study shows promise in reducing surgical risks associated with surgical bleeding
Date:8/13/2007

CHICAGO (August 10, 2007) Surgeons may have a new patient safety tool to stop moderate surgical bleeding without some of the concerns associated with the current standard blood-clotting treatment. New research published in the August issue of the Journal of the American College of Surgeons shows that recombinant human thrombin (rhThrombin) reduces the risk of surgical complications associated with the use of plasma-derived bovine thrombin (bThrombin), which is currently the only commercially available stand-alone thrombin used to improve clotting during surgical procedures and stop bleeding.

Each year, bThrombin is used to treat more than one million patients who undergo surgical procedures in the United States. However, approximately 20 percent of these patients develop antibodies against bovine coagulation factors that can cross-react with human coagulation proteins and possibly lead to adverse effects, including severe bleeding and thrombosis. Due to these safety concerns, rhThrombin was developed as an alternative to bThrombin.

We constantly look for new ways to reduce risks in surgery and stopping surgical bleeding safely and effectively is of foremost interest to surgeons. The results from this phase III trial show that we can stop bleeding in 95 percent of patients within 10 minutes and do so without introducing foreign proteins that can carry greater risk of development of antibodies, said William C. Chapman, MD, FACS, Department of Surgery, Washington University, St. Louis (MO) School of Medicine. Im most encouraged by the increasing evidence that recombinant technology is safe and effective because it means that we may be able to avoid using blood or blood products from other people or animals and automatically diminish the risk of infection and the associated immunologic responses that have been noted in the past.

The randomized, double-blind comparative study included 411 patients who underwent surgical procedures at 34 U.S. medical centers across the country. One group of patients (n=206) was treated with bThrombin and a second group (n=205) was treated with rhThrombin, both of which were applied topically to the bleeding site(s) in combination with an absorbable gelatin sponge. The primary endpoint was the time it took for hemostasis to occur, as measured by the incidence of hemostasis within 10 minutes. Secondary endpoints included the incidence and severity of adverse events and the incidence of antiproduct antibodies.

The study demonstrated that both rhThrombin and bThrombin had comparable efficacy, with 95 percent of patients in each treatment group achieving hemostasis within 10 minutes. The two treatments had similar safety profiles, although antibody development was significantly lower in patients treated with rhThrombin compared with bThrombin (1.5 percent versus 21.5 percent, respectively).


'/>"/>

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 ... ... Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American ... The organization, which plans to publish the first ANSI-approved GMP standard for ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic ... involve many repetitive steps and often scientists require many different versions of DNA. ... and results in a lower error rate and cost saving for reagents and ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... ... ... the eastern suburbs and South Hills of Pittsburgh now have easier access ... western Pennsylvania only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes ...
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the ... the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony ... Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Maxor National Pharmacy Services, LLC ("Maxor"), a ... named Leah Bailey as General Counsel.  Bailey will ... company. With more than 13 years of ... focused on health care, Bailey joins the Maxor team ... Bailey advised the PBM, Specialty, and Mail Order business ...
(Date:3/29/2017)... , March 29, 2017  Designers of primary ... reduce solution size by 50% and extend battery life ... power management integrated circuit (PMIC) from Maxim Integrated Products, ... supports a low input voltage of just 0.7V for ... and Silver Oxide, as well as the more common ...
(Date:3/29/2017)... Stryker announced today that it has been ... partnership with Great Place to Work (GPTW). We ranked ... list highlights the top U.S. companies with 1,000 or ... demonstrating respect, compassion and concern for their employees, their ... the companies on the list, GPTW asked more than ...
Breaking Medicine Technology: